BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17532236)

  • 1. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.
    Stanulla M; Cario G; Meissner B; Schrauder A; Möricke A; Riehm H; Schrappe M
    Blood Cells Mol Dis; 2007; 39(2):160-3. PubMed ID: 17532236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of childhood acute lymphoblastic leukemia.
    Stanulla M; Schrappe M
    Semin Hematol; 2009 Jan; 46(1):52-63. PubMed ID: 19100368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
    Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
    J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
    J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
    Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
    Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference.
    Herold R; von Stackelberg A; Hartmann R; Eisenreich B; Henze G
    J Clin Oncol; 2004 Feb; 22(3):569-70; author reply 570-1. PubMed ID: 14752084
    [No Abstract]   [Full Text] [Related]  

  • 8. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
    Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
    J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group.
    Reismüller B; Attarbaschi A; Peters C; Dworzak MN; Pötschger U; Urban C; Fink FM; Meister B; Schmitt K; Dieckmann K; Henze G; Haas OA; Gadner H; Mann G;
    Br J Haematol; 2009 Feb; 144(4):559-70. PubMed ID: 19077160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of BFM trials for childhood ALL.
    Schrappe M
    Ann Hematol; 2004; 83 Suppl 1():S121-3. PubMed ID: 15124702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia.
    Schrappe M
    Radiat Prot Dosimetry; 2008; 132(2):130-3. PubMed ID: 19017727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of childhood acute myeloid leukemia.
    ter Bals E; Kaspers GJ
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):917-29. PubMed ID: 16221060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular diagnostics in the treatment of childhood acute lymphoblastic leukemia.
    Rubnitz JE
    J Biol Regul Homeost Agents; 2000; 14(3):182-6. PubMed ID: 11037050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monitoring minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
    Zuna J; Hrusák O; Kalinová M; Muzíková K; Zörnerová T; Starý J; Trka J
    Vnitr Lek; 2000 Aug; 46(8):465-9. PubMed ID: 11048511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of late cell cycle genes and an increased proliferative capacity characterize very early relapse of childhood acute lymphoblastic leukemia.
    Kirschner-Schwabe R; Lottaz C; Tödling J; Rhein P; Karawajew L; Eckert C; von Stackelberg A; Ungethüm U; Kostka D; Kulozik AE; Ludwig WD; Henze G; Spang R; Hagemeier C; Seeger K
    Clin Cancer Res; 2006 Aug; 12(15):4553-61. PubMed ID: 16899601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
    Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
    J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of childhood and adult acute lymphoblastic leukaemia.
    Liesner R; Goldstone AH
    J Intern Med Suppl; 1997; 740():29-36. PubMed ID: 9350179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia.
    Campana D; Coustan-Smith E
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):1-19. PubMed ID: 11987913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of adult acute lymphoblastic leukemia.
    Gökbuget N; Hoelzer D
    Semin Hematol; 2009 Jan; 46(1):64-75. PubMed ID: 19100369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.